California judge rules Allergan, Endo, Johnson & Johnson, and Teva not liable for state's opioid crisis; CDC panel to decide on approval of and recommendations for Pfizer/BioNTech's COVID-19 vaccine in children aged 5 to 11 years; screen time among teenagers more than doubled during the pandemic.
Yesterday, Superior Court Judge Peter J. Wilson of California rejected claims that 4 drug companies—Allergan, Endo, Johnson & Johnson, and Teva—used false and misleading marketing to promote the sale of prescription opioids. Reported by NPR, the ruling indicates that the 4 drug companies cannot be held liable for California’s opioid crisis. If found guilty, they would have had to pay for several costly public health and drug treatment programs. There are several other opioid lawsuits in state and federal courts nationwide, with cases currently underway in New York, Ohio, and West Virginia.
A special advisory panel from the CDC is meeting today to consider recommendations for administering Pfizer/BioNTech’s COVID-19 vaccine in children aged 5 to 11 years, with The Associated Press reporting that the Biden administration, anticipating approval from advisors, is beginning to assemble and ship millions of shots. Delivering a dose that is one-third of the vaccine given to adults, White House Coronavirus Response Coordinator Jeff Zients said the government has enough vaccine for all 28 million young children of the age group. Pending approval, the first shots could be given to children by midweek. Parents will be able to go to vaccines.gov and filter on vaccines for children 5 to 11 to find a location near them that is offering the vaccine.
As reported by USA Today, a study published yesterday in JAMA Pediatrics found that screen time among teenagers outside of virtual school more than doubled from 3.8 hours per day before the pandemic to 7.7 hours per day in 2020. Leveraging data from the Adolescent Brain Cognitive Development Study, the data also show that children of color and those of lower-income families reported greater screen time than their White, wealthier counterparts. Because participants were asked to self-report screen use, wellness experts noted that study projections may be underreported and that estimates are likely greater in teens.
Hospital Stays and Probable Dementia as Predictors of Relocation to Long-Term Care Facilities
October 22nd 2024This article explores late-life relocations in patients with dementia, hospital stays, and their implications for health care policy, geriatric care, and future research priorities.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More